High-dosage of chloroquine was proven dangerous for the heart. (Image via CNN Indonesia)

Brazil stops chloroquine test after heart complication detected

The trial run for chloroquine as a cure for the novel coronavirus disease (COVID-19) was stopped after it was known to cause complications. The clinical trial in Brazil on participants consuming high-dosage chloroquine resulted in a dangerous palpitation. Initially, the experiment was conducted to test the effectiveness and security of chloroquine for COVID-19, involving 440 COVID-19 positive patients.

The participants were divided into two groups. The researchers gave a 600 mg dosage of chloroquine twice a day for 10 days for some, and the other group was given a 450 mg dosage of chloroquine for 5 days.

After monitoring 81 patients, the researchers saw some worrisome symptoms. In a few days of medication, many patients of the high-dosage group experienced palpitations. Two patients in the group died after the abnormal palpitation went on.

Hence, after the deaths, the researchers stopped the usage and trial for chloroquine on the high-dosage group. The researchers also warned doctors all around the world to refrain from prescribing high-dosage chloroquine for COVID-10 patients in order to prevent unwanted deaths.

Besides Brazil, hospitals in France also stopped hydroxychloroquine medication for COVID-19 patients after seeing the same palpitating results.

Chloroquine and hydroxychloroquine are used to treat malaria. Then, they are tested to treat COVID-19. The Indonesian government also purchased chloroquine to treat COVID-19 patients. While it is tolerable by the body easily, the main complication always goes to the pulse. Therefore, medicine is not recommended for those who suffer from arrhythmia.

Source: https://bit.ly/2XAXENB